ArticleCancer cell international2026
TERT promoter C228T and C250T mutation detection combined with cytology in the diagnosis of urothelial carcinomas: a real-world cohort study in a Chinese population.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundUrothelial carcinoma (UC) is a malignancy of the urinary tract characterized by a high recurrence rate, imposing a substantial healthcare burden. Although cystoscopy and ureteroscopy remain the diagnostic gold standards, their invasive nature causes considerable discomfort during surveillance. Somatic mutations in the promoter region of the telomerase reverse transcriptase (TERT) gene are common events in UC and serve as promising noninvasive urinary biomarkers. This study aimed to evaluate the diagnostic utility of combining urinary TERT promoter mutation detection with cytology for UC diagnosis and surveillance, potentially serving as an indicator for cystoscopy application.
methodsIn this prospective study, 414 samples were collected, including 307 clinical patients, 25 non-tumorous hematuria patients, and 81 healthy controls. Droplet digital PCR (ddPCR) was used to detect TERT promoter mutations (C228T, C250T) in urinary cell-free DNA (cfDNA), alongside conventional cytology for comparison and combination analysis.
resultsThe sensitivity and specificity of TERT promoter mutation detection were 48.6% and 84.7%, respectively, whereas those of cytology were 36.8% and 96.6%, respectively. Combining TERT mutation detection with cytology significantly improved diagnostic performance (sensitivity = 70.8%, specificity = 81.4%, AUC = 0.868). The mutant allele fraction (MAF) of TERT promoter mutations in UC patients was significantly higher than that in controls and showed an increasing trend with disease severity.
conclusionsUrinary TERT promoter mutation detection, particularly when integrated with cytology, enhances the diagnostic sensitivity and overall accuracy for UC. The MAF of TERT promoter mutations correlated with disease severity, indicating potential clinical utility. This combined noninvasive assay may serve as a practical adjunct for UC diagnosis and surveillance, complementing conventional cystoscopy in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.